Peptides Aren’t Legal or Illegal as a Category. The Compounding System Decides Case by Case.
There is no single federal law that bans or permits “peptides.” What actually governs whether a specific compound can legally be sold is a narrow exemption system, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and most peptides marketed as research chemicals online never clear it.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
- There's no blanket federal ban on peptides as a category, legality is decided substance by substance.
- Sections 503A and 503B of the FD&C Act set the actual eligibility test, tied to USP monographs, FDA-approved-drug status, or a specific bulks list.
- Labeling a product "research use only" has no legal effect on whether it's actually being marketed for human use.
- FDA sent dozens of warning letters across 2024–2026 targeting the exact peptides sold on research-chemical sites.
Photo: Wesley Tingey / UnsplashHow the compounding system actually works.
Two sections of the Federal Food, Drug, and Cosmetic Act create narrow exemptions from the normal drug-approval process for compounded products. Section 503A covers traditional pharmacy and physician compounding, generally for a specific patient. Under it, a bulk drug substance can only be used if it complies with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, is a component of an FDA-approved drug product, or appears on the FDA’s 503A bulks list.
Section 503B covers “outsourcing facilities,” which compound in larger batches without a patient-specific prescription. The eligibility test is narrower still: the bulk substance must appear on a separate 503B bulks list identifying substances with a demonstrated clinical need, or the compounded product must appear on FDA’s drug shortage list at the time of compounding.
Neither pathway is a general permission slip. A substance has to affirmatively clear one of these tests. Most peptides sold as “research chemicals”, BPC-157, TB-500, retatrutide, cagrilintide, and most of the compounds profiled on this site, clear none of them: they’re not USP-monographed, they’re not components of an approved drug, and they don’t appear on either bulks list. FDA has said this explicitly, in writing, about specific compounds: retatrutide and cagrilintide, for example, “cannot be used in compounding under federal law.”
On top of the eligibility test, FDA sorts substances nominated for these lists into categories. Category 1 substances have enough supporting information for FDA to evaluate and may be eligible. Category 2 substances raise significant safety concerns FDA has identified. Category 3 substances were nominated with insufficient information to evaluate at all. A substance can move between these categories, or drop off the list entirely if a nomination is withdrawn, which is exactly what makes a snapshot of “current status” perishable.
Why “research use only” doesn’t confer legality.
A huge share of the peptide market runs on a disclaimer: “for research purposes only, not for human consumption.” That label describes an intended use. It doesn’t change what a product actually is, and it doesn’t bind the FDA’s own read of the evidence.
When FDA reviews a seller’s site and finds dosing instructions, health claims, and marketing clearly aimed at people rather than laboratories, it treats the product as what it’s actually being sold as, not what the label says. Warning letters reviewed for this article show FDA quoting a seller’s own “research purposes only” language directly alongside the seller’s own dosing claims and health-benefit marketing, as evidence the disclaimer doesn’t match the real conduct. The label doesn’t create a safe harbor.
The pattern is a system, not an isolated warning.
FDA doesn’t send one letter and stop. On a single day, September 9, 2025, it sent at least six warning letters to different sellers, all citing the identical 503A/503B reasoning against retatrutide. In December 2025, a separate letter to a compounding-ingredient distributor, Darmerica, LLC, named cagrilintide acetate specifically as an active ingredient ineligible for 503A compounding. In March 2026, a letter to Prime Sciences cited the same reasoning against a different seller entirely. The targets range across the supply chain: API distributors, compounders, telehealth resellers, direct-to-consumer sites.
The throughline across every letter reviewed for this article is the same: not one-off discretionary enforcement against a single bad actor, but a repeatable legal test (the 503A/503B eligibility gate) applied consistently across sellers and substances. That’s the actual mechanism worth understanding, more than any single letter’s specific target.
What this means for a specific peptide.
Everything above is the mechanism. Whether a specific compound, BPC-157, Semax, Retatrutide, is currently compounding-eligible, under which category, and what enforcement action exists against it specifically, changes on an ongoing basis and is covered on that compound’s own evidence report, not restated here.
Two different questions come up constantly alongside this one: whether a specific compound is safe to use is a separate question from whether it’s legal to compound, see Are Peptides Safe? for that. And a short list of peptides sidesteps this entire framework because they’re actual FDA-approved drugs, see FDA-Approved Peptides for that roster.
Every claim above, traced back.
FDA’s own 503A/503B framework pages, its personal-importation policy, and four warning letters spanning September 2025 through March 2026. Click through and check them yourself.
Legal status questions, answered.
It depends entirely on which peptide and what it's sold as, not on "peptides" as a category. A compounded drug product is only lawful if its bulk substance clears a specific eligibility test under section 503A or 503B of the FD&C Act. Most peptides marketed online as "research chemicals" fail that test outright, which is exactly what the FDA's warning letters to sellers cite as the violation.
Section 503A covers traditional pharmacy and physician compounding, generally for a specific patient. Section 503B covers "outsourcing facilities," which compound in larger batches without a patient-specific prescription. Both require the bulk substance to either comply with a USP/NF monograph, be a component of an FDA-approved drug, or appear on the relevant bulks list, whichever applies.
No. That label describes an intended use, not a legal shield. When the FDA reviews a seller's actual marketing, dosing instructions, and product claims and concludes the product is really being sold for human use, the "research use only" disclaimer doesn't change the violation. The FDA has said this directly in warning letters that quote a seller's own "research purposes" language right next to evidence the product was marketed for human consumption.
The FDA's own personal-importation guidance states plainly that "in most circumstances, it is illegal for individuals to import drugs...into the U.S. for personal use" when those drugs aren't FDA-approved. That's the letter of the policy. In practice, every enforcement action reviewed for this article, warning letters, docket actions, was directed at sellers, distributors, and compounders, not individual buyers. The two are legally distinct questions, and this article can only speak to what's actually been enforced, not to buyer-side risk that hasn't been documented.
Because it does, on an ongoing basis. The FDA's bulk-substance nomination categories are periodically revisited by its Pharmacy Compounding Advisory Committee, nominations get withdrawn and re-evaluated, and substances move on and off lists. CJC-1295 and ipamorelin, for example, were both removed from the FDA's Category 2 list in September 2024 after their nominations were withdrawn, then formally voted against for inclusion on the 503A list in separate October and December 2024 committee meetings. A status snapshot from even a few months ago can be stale.
Keep researching.
Checking one compound's current status beats trusting a snapshot from months ago.
Create your account to check any peptide's evidence and regulatory status before it goes anywhere near your body.